KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Assets (2016 - 2025)

Novavax (NVAX) has 16 years of Assets data on record, last reported at $1.2 billion in Q4 2025.

  • For Q4 2025, Assets fell 24.6% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, down 24.6%, while the annual FY2025 figure was $1.2 billion, 24.6% down from the prior year.
  • Assets reached $1.2 billion in Q4 2025 per NVAX's latest filing, roughly flat from $1.2 billion in the prior quarter.
  • Across five years, Assets topped out at $2.8 billion in Q1 2022 and bottomed at $1.2 billion in Q4 2025.
  • Average Assets over 5 years is $1.9 billion, with a median of $1.8 billion recorded in 2023.
  • Peak YoY movement for Assets: soared 695.07% in 2021, then plummeted 45.58% in 2023.
  • A 5-year view of Assets shows it stood at $2.6 billion in 2021, then decreased by 12.34% to $2.3 billion in 2022, then decreased by 20.42% to $1.8 billion in 2023, then fell by 13.19% to $1.6 billion in 2024, then fell by 24.6% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $1.2 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.3 billion in Q2 2025.